Newsletter

358570 - GI Innovation, Inc.

358570 Summary
Biopharma
Stock Price & Overview
₩8,090 +470 (+6.17%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩8,090  ≈ US$6  ·  Market cap ₩0.5tn (≈ $373m)
Why this page exists. Korean issuers file to DART, not the SEC, and almost nothing is published in English. Titles here are translated; where kstock has read the filing, the row carries the explanation and the amount in won and dollars. How we pick »

358570 DART Filings

DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing08/21/26title translated
DART

Half-Year Report

Periodic08/14/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment approved)

Filing07/10/26title translated
DART

Material matter affecting investment judgment (clinical trial plan approval)

Filing06/30/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing06/08/26title translated
DART

Material matter affecting investment judgment (clinical trial plan approval)

Filing05/29/26title translated
DART

Material matter affecting investment judgment (clinical trial plan applied for)

Filing05/28/26title translated
DART

Quarterly Report

Periodic05/15/26title translated
DART

Board Resolution — Cancellation of Shares

Buyback05/13/26title translated
DART

Grant of stock options

Filing05/13/26title translated
10 routine filings (insider holdings reports, IR schedules)DART

5% Ownership Report — Large Holdings

Ownership09/04/26title translated
DART

5% Ownership Report — Short Form

Ownership08/20/26title translated
DART

Insider / Major Shareholder Holdings Report ×6

Ownership08/10/26title translated
DART

5% Ownership Report — Large Holdings

Ownership08/06/26title translated
DART

Insider / Major Shareholder Holdings Report ×2

Ownership07/23/26title translated
DART

Insider / Major Shareholder Holdings Report

Ownership07/13/26title translated
DART

5% Ownership Report — Large Holdings

Ownership07/06/26title translated
DART

Insider / Major Shareholder Holdings Report

Ownership07/06/26title translated
DART

5% Ownership Report — Large Holdings

Ownership06/08/26title translated
DART

Insider / Major Shareholder Holdings Report ×6

Ownership06/05/26title translated
20 filings on file, grouped where one event produced many. Source: DART, operated by Korea's Financial Supervisory Service.

Similar to 358570

SymbolLast Price
085660Chabiotech Co., Ltd.₩8,090
+2.1%
476060Onconic Therapeutics, Inc.₩16,440
-3.9%
041960Komipharm International Co., Ltd.₩9,710
+3.5%
317450Myungin Pharm₩44,650
+0.0%
001060JW Pharmaceutical₩27,500
+1.3%
456160G2GBIO, Inc.₩37,950
+5.7%
019170Shinpoong Pharmaceutical Co., Ltd.₩10,010
-0.9%
086900Medy-Tox, Inc.₩69,600
+0.4%
397030April Bio Co., Ltd.₩17,800
+6.1%
249420Ildong Pharm₩15,030
-0.5%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.